Company Description
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases.
The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 7, 2015 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Neal Walker |
Contact Details
Address: 701 Lee Road, Suite 103 Wayne, Pennsylvania 19087 United States | |
| Phone | 484 324 7933 |
| Website | aclaristx.com |
Stock Details
| Ticker Symbol | ACRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001557746 |
| CUSIP Number | 00461U105 |
| ISIN Number | US00461U1051 |
| Employer ID | 46-0571712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Neal S. Walker D.O., M.D. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Hugh M. Davis Ph.D. | President, Chief Operating Officer and Director |
| Kevin Balthaser | Chief Financial Officer |
| Dr. Joseph Monahan Ph.D. | Chief Scientific Officer |
| Matthew Rothman J.D. | General Counsel and Corporate Secretary |
| Dr. Jon Jacobsen Ph.D. | Senior Vice President of Chemistry |
| James Loerop | Chief Business Officer |
| Steve Tucker | Senior Vice President of Project Leadership |
| Ajay Aggarwal M.B.A., M.D. | Senior Vice President of Clinical Development |
| Dr. Steven Knapp M.S. Pharm.D. | Executive Vice President, Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 7, 2025 | EFFECT | Notice of Effectiveness |
| Feb 27, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 31, 2024 | EFFECT | Notice of Effectiveness |
| Dec 31, 2024 | 424B3 | Prospectus |
| Dec 26, 2024 | UPLOAD | Filing |